Aerosol-based efficient delivery of clarithromycin, a macrolide antimicrobial agent, to lung epithelial lining fluid and alveolar macrophages for treatment of respiratory infections

Journal of Aerosol Medicine and Pulmonary Drug Delivery

Volumn 25, Issue 2, 2012, Pages 110-115

  Togami, Kohei ^a,b   Chono, Sumio ^a   Morimoto, Kazuhiro ^a  

^a HOKKAIDO INSTITUTE OF TECHNOLOGY   (Japan)

^b OHU UNIVERSITY   (Japan)

Author keywords

aerosol based pulmonary drug delivery system; clarithromycin; lung epithelial lining fluid and alveolar macrophages; macrolides; PK PD; respiratory infections

Indexed keywords

CLARITHROMYCIN;

AEROSOL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; LUNG ALVEOLUS EPITHELIUM; LUNG ALVEOLUS MACROPHAGE; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; RAT; RESPIRATORY TRACT INFECTION;

ADMINISTRATION, INHALATION; ADMINISTRATION, ORAL; AEROSOLS; ANIMALS; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; BRONCHOALVEOLAR LAVAGE FLUID; CLARITHROMYCIN; DRUG DELIVERY SYSTEMS; LUNG; MACROPHAGES, ALVEOLAR; MALE; MICROBIAL SENSITIVITY TESTS; RATS; RATS, SPRAGUE-DAWLEY; RESPIRATORY TRACT INFECTIONS; TIME FACTORS;

EID: 84859398578     PISSN: 19412711     EISSN: 19412703     Source Type: Journal    
DOI: 10.1089/jamp.2011.0894     Document Type: Article

References (54)

1. Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, OBrien KL, Roca A, Wright PF, Bruce N, Chandran A, Theodoratou E, Sutanto A, Sedyaningsih ER, Ngama M, Munywoki PK, Kartasasmita C, Simoes EA, Rudan I, Weber MW, and Campbell H: Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and metaanalysis. Lancet. 2010;375:1545-1555.
2. Waterer G, and Wunderink R: Respiratory infections: a current and future threat. Respirology. 2009;14:651-655.
3. Wong SS, and Yuen KY: Antiviral therapy for respiratory tract infections. Respirology. 2008;13:950-971.
4. Densen P, and Mandell GL: Phagocyte strategy vs. microbial tactics. Rev Infect Dis. 1980;2:817-838.
5. Horwitz MA, and Silverstein SC: Influence of the Escherichia coli capsule on complement fixation and on phagocytosis and killing by human phagocytes. J Clin Invest. 1980;65: 82-94.
6. Krieg DP, Helmke RJ, German VF, and Mangos JA: Resistance of mucoid Pseudomonas aeruginosa to nonopsonic phagocytosis by alveolar macrophages in vitro. Infect Immun. 1988;56:3173-3179.
7. Peterson PK, Verhoef J, Sabath LD, and Quie PG: Effect of protein A on staphylococcal opsonization. Infect Immun. 1977;15:760-764.
8. Stiver HG, Zachidniak K, and Speert DP: Inhibition of polymorphonuclear leukocyte chemotaxis by the mucoid exopolysaccharide of Pseudomonas aeruginosa. Clin Invest Med. 1988;11:247-252.
9. Ferrari G, Langen H, Naito M, and Pieters J: A coat protein on phagosomes involved in the intracellular survival of mycobacteria. Cell. 1999;97:435-447.
10. Greub G, and Raoult D: Microorganisms resistant to freeliving amoebae. Clin Microbiol Rev. 2004;17:413-433.
11. Harb OS, Gao LY, and Abu Kwaik Y: From protozoa to mammalian cells: a new paradigm in the life cycle of intracellular bacterial pathogens. Environ Microbiol. 2000;2: 251-265.
12. Mckinney JD, Honer Zu Bentrup K, Munoz-Elias EJ, Miczak A, Chen B, Chan WT, Swenson D, Sacchettini JC, Jacobs WR Jr, and Russell DG: Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase. Nature. 2000;406:735-738.
13. Portnoy DA, Chakraborty T, Goebel W, and Cossart P: Molecular determinants of Listeria monocytogenes pathogenesis. Infect Immun. 1992;60:1263-1267.
14. Vazquez-Boland JA, Kuhn M, Berche P, Chakraborty T, Dominguez-Bernal G, Goebel W, Gonzalez-Zorn B, Wehland J, and Kreft J: Listeria pathogenesis and molecular virulence determinants. Clin Microbiol Rev. 2001;14: 584-640.
15. Chandran A, Watt JP, and Santosham M: Prevention of Haemophilus influenzae type b disease: past success and future challenges. Expert Rev Vaccines. 2005;4:819-827.
16. Doganay M: Listeriosis: clinical presentation. FEMS Immunol Med Microbiol. 2003;35:173-175.
17. Ellner JJ, Goldberger MJ, and Parenti DM: Mycobacterium avium infection and AIDS: a therapeutic dilemma in rapid evolution. J Infect Dis. 1991;163:1326-1335.
18. Frieden TR, Sterling TR, Munsiff SS, Watt CJ, and Dye C: Tuberculosis. Lancet. 2003;362:887-899.
19. Kipnis E, Sawa T, and Wiener-Kronish J: Targeting mechanisms of Pseudomonas aeruginosa pathogenesis. Med Mal Infect. 2006;36:78-91.
20. Nara C, Tateda K, Matsumoto T, Ohara A, Miyazaki S, Standiford TJ, and Yamaguchi K: Legionella-induced acute lung injury in the setting of hyperoxia: protective role of tumour necrosis factor-alpha. J Med Microbiol. 2004;53: 727-733.
21. Shorr AF: Preventing pneumonia: the role for pneumococcal and influenza vaccines. Clin Chest Med. 2005;26:123-134.
22. Tarnvik A, and Berglund L: Tularaemia. Eur Respir J. 2003; 21:361-373.
23. Tsai MH, Huang YC, Chen CJ, Lin PY, Chang LY, Chiu CH, Tsao KC, Huang CG, and Lin TY: Chlamydial pneumonia in children requiring hospitalization: effect of mixed infection on clinical outcome. J Microbiol Immunol Infect. 2005;38: 117-122.
24. Tamm M, Todisco T, Feldman C, Garbino J, Blasi F, Hogan P, De Caprariis PJ, and Hoepelman IM: Clinical and bacteriological outcomes in hospitalised patients with community- acquired pneumonia treated with azithromycin plus ceftriaxone, or ceftriaxone plus clarithromycin or erythromycin: a prospective, randomised, multicentre study. Clin Microbiol Infect. 2007;13:162-171.
25. Yoshida H, and Furuta T: Tissue penetration properties of macrolide antibiotics-comparative tissue distribution of erythromycin-stearate, clarithromycin, roxithromycin and azithromycin in rats. Jpn J Antibiot. 1999;52:497-503.
26. Carter BL, Woodhead JC, Cole KJ, and Milavetz G: Gastrointestinal side effects with erythromycin preparations. Drug Intell Clin Pharm. 1987;21:734-738.
27. Sharma NL, and Mahajan VK: Onycholysis: an unusual side effect of roxithromycin. Indian J Dermatol Venereol Leprol. 2005;71:49-50.
28. Westphal JF, Vetter D, and Brogard JM: Hepatic side-effects of antibiotics. J Antimicrob Chemother. 1994;33:387-401.
29. Antonini JM, and Reasor MJ. Accumulation of amiodarone and desethylamiodarone by rat alveolar macrophages in cell culture. Biochem Pharmacol. 1991;42(Suppl):S151-S156.
30. Rennard SI, Basset G, Lecossier D, ODonnell KM, Pinkston P, Martin PG, and Crystal RG: Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution. J Appl Physiol. 1986;60:532-538.
31. Kohno Y, Yoshida H, Suwa T, and Suga T: Uptake of clarithromycin by rat lung cells. J Antimicrob Chemother. 1990; 26:503-513.
32. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72: 248-254.
33. Hunt C, Macgregor R, and Siegel R: Engineering targeted in vivo drug delivery. I. The physiological and physicochemical principles governing opportunities and limitations. Pharm Res. 1986;3:333-334.
34. Okamoto H, Miyazaki S, Tateda K, Ishii Y, and Yamaguchi K: Comparative in vitro activity of telithromycin (HMR 3647), three macrolides, amoxycillin, cefdinir and levofloxacin against Gram-positive clinical isolates in Japan. J Antimicrob Chemother. 2000;46:797-802.
35. Bozdogan B, Clark C, Bryskier A, Jacobs MR, and Appelbaum PC: Activities of HMR 3787 and RU 64399 compared with those of four other agents against Haemophilus influenzae and Haemophilus parainfluenzae. Antimicrob Agents Chemother. 2003;47:405-407.
36. Zhanel GG, Palatnick L, Nichol KA, Low DE, and Hoban DJ: Antimicrobial resistance in Haemophilus influenzae and Moraxella catarrhalis respiratory tract isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002. Antimicrob Agents Chemother. 2003;47:1875-1881.
37. Miyashita N, Fukano H, Yoshida K, Niki Y, and Matsushima T: In vitro activity of cethromycin, a novel antibacterial ketolide, against Chlamydia pneumoniae. J Antimicrob Chemother. 2003;52:497-499.
38. Krishnan MY, Manning EJ, and Collins MT: Comparison of three methods for susceptibility testing of Mycobacterium avium subsp. paratuberculosis to 11 antimicrobial drugs. J Antimicrob Chemother. 2009;64:310-316.
39. Periti Pand Mazzei T: Clarithromycin: pharmacokinetic and pharmacodynamic interrelationships and dosage regimen. J Chemother. 1999;11:11-27.
40. Baldwin DR, Honeybourne D, and Wise R: Pulmonary disposition of antimicrobial agents: methodological considerations. Antimicrob Agents Chemother. 1992;36:1171-1175.
41. Wang F, Daugherty B, Keise LL, Wei Z, Foley JP, Savani RC, and KovalM: Heterogeneity of claudin expression by alveolar epithelial cells. Am J Respir Cell Mol Biol. 2003;29:62-70.
42. Campbell L, Abulrob AN, Kandalaft LE, Plummer S, Hollins AJ, Gibbs A, and Gumbleton M: Constitutive expression of p-glycoprotein in normal lung alveolar epithelium and functionality in primary alveolar epithelial cultures. J Pharmacol Exp Ther. 2003;304:441-452.
43. Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM, and Pastan I: Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA. 1987;84: 265-269.
44. Zaman GJ, Versantvoort CH, Smit JJ, Eijdems EW, De Haas M, Smith AJ, Broxterman HJ, Mulder NH, De Vries EG, Baas F, and Borst P: Analysis of the expression of MRP, the gene for a new putative transmembrane drug transporter, in human multidrug resistant lung cancer cell lines. Cancer Res. 1993;53:1747-1750.
45. Togami K, Chono S, and Morimoto K: Distribution characteristicsof clarithromycin and azithromycin, macrolide antimicrobial agents used for treatment of respiratory infections, in lung epithelial lining fluid and alveolar macrophages. Biopharm Drug Dispos. 2011;32:389-397.
46. Vazifeh D, Abdelghaffar H, and Labro MT: Effect of telithromycin (HMR 3647) on polymorphonuclear neutrophil killing of Staphylococcus aureus in comparison with roxithromycin. Antimicrob Agents Chemother. 2002;46: 1364-1374.
47. Mouton JW, Dudley MN, Cars O, Derendorf H, and Drusano GL: Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs. Int J Antimicrob Agents. 2002;19:355-358.
48. Mouton JW, Dudley MN, Cars O, Derendorf H, and Drusano GL: Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J Antimicrob Chemother. 2005;55:601-607.
49. Geist LJ, Powers LS, Monick MM, and Hunninghake GW: Asbestos stimulation triggers differential cytokine release from human monocytes and alveolar macrophages. Exp Lung Res. 2000;26:41-56.
50. Liu HW, Anand A, Bloch K, Christiani D, and Kradin R: Expression of inducible nitric oxide synthase by macrophages in rat lung. Am J Respir Crit Care Med. 1997;156: 223-228.
51. Mao JT, Roth MD, Serio KJ, Baratelli F, Zhu L, Holmes EC, Strieter RM, and Dubinett SM: Celecoxib modulates the capacity for prostaglandin E2 and interleukin-10 production in alveolar macrophages from active smokers. Clin Cancer Res. 2003;9:5835-5841.
52. Ogle CK, Ogle JD, Johnson C, Keynton L, and Alexander JW: The production of C3, PGE2 and TxB2 by splenic, alveolar, and peritoneal guinea pig macrophages. Prostaglandins. 1988;36:279-289.
53. Rennard SI, Hunninghake GW, Bitterman PB, and Crystal RG: Production of fibronectin by the human alveolar macrophage: mechanism for the recruitment of fibroblasts to sites of tissue injury in interstitial lung diseases. Proc Natl Acad Sci USA. 1981;78:7147-7151.
54. Weissbach S, Neuendank A, Pettersson M, Schaberg T, and Pison U: Surfactant protein A modulates release of reactive oxygen species from alveolar macrophages. Am J Physiol. 1994;267:L660-L666.